CG Oncology, Inc. (CGON) Price & Analysis

Compare

242 Followers

CGON Stock Chart & Stats

$44.84

-$0.55(-1.77%)

At close: Jan 08 4:00 PM EST

$44.84

-$0.55(-1.77%)

Day’s Range― - ―

52-Week Range$14.80 - $45.78

Previous Close$30.46

Volume740.02K

Average Volume (3M)893.73K

Market Cap

$3.62B

Enterprise Value$2.42B

Total Cash (Recent Filing)$680.26M

Total Debt (Recent Filing)$7.24M

Price to Earnings (P/E)―

Beta1.74

Next Earnings

Mar 27, 2026

EPS Estimate

-0.61

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.57

Shares Outstanding80,666,176

10 Day Avg. Volume891,199

30 Day Avg. Volume893,729

Financial Highlights & Ratios

PEG Ratio-0.53

Price to Book (P/B)2.44

Price to Sales (P/S)1573.67

P/FCF Ratio-22.70

Enterprise Value/Market Cap0.67

Enterprise Value/Revenue1.11K

Enterprise Value/Gross Profit5.48K

Enterprise Value/Ebitda-14.66

Forecast

1Y Price Target

$70.09

Price Target Upside56.31% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-2.18

Revenue Forecast (FY)$2.70M

Bulls Say, Bears Say

Bulls Say

Clinical Trials & EfficacyCretostomogene demonstrated a 75.5% anytime complete response rate with no treatment-related discontinuations, indicating a strong efficacy and safety profile.

Market OpportunityCG Oncology is developing an oncolytic virus that is considered potently effective and safe, with the potential to dominate the intermediate-/high-risk NMIBC markets.

Regulatory PathwayCG Oncology has initiated the rolling BLA submission process for creto, which is supported by Breakthrough and Fast Track designations, potentially allowing for an accelerated approval path.

Bears Say

Investor SkepticismShort interest is high at 27.5% of the float, which may indicate investor skepticism or potential volatility.

Market SentimentShort interest is 20.2% of the float, indicating a significant portion of investors are betting against the stock.

Operational ChallengesThe timeline for completing all BLA modules by mid-January may be aggressive, requiring completion of several tasks including streamlined administration testing and validation of creto's stability.

CG Oncology, Inc. News

These 3 Stocks Have Strong Upside Potential, Say Five-Star Analysts – 11/27/2025

If you’re looking for investment ideas right now, several top-rated Wall Street analysts (each with five-star ratings) believe...

2d ago

BTDR

CGON

CG Oncology appoints Rossi to its Board of Directors

CG Oncology (CGON) announced the appointment of Christina Rossi to its Board of Directors. Additionally, Simone Song, Senior...

3d ago

CGON

CG Oncology initiated with a Buy at Truist

Truist analyst Gregory Renza initiated coverage of CG Oncology (CGON) with a Buy rating and $62 price target...

5d ago

CGON

CG Oncology price target raised to $61 from $53 at RBC Capital

RBC Capital raised the firm’s price target on CG Oncology (CGON) to $61 from $53 and keeps an...

12d ago

CGON

CG Oncology price target lowered to $60 from $62 at BofA

BofA lowered the firm’s price target on CG Oncology (CGON) to $60 from $62 as the firm pushes...

15d ago

CGON

CG Oncology reports Q3 EPS (57c), consensus (55c)

Reports Q3 revenue $1.666M, consensus $72.56k. “I am proud of the meaningful progress we have made over the...

15d ago

CGON

CG Oncology expects cash to fund operations into 1H of 2028

Cash and cash equivalents and marketable securities as of September 30, 2025 were $680.3 million, compared with $661.1...

15d ago

CGON

enGene price target raised to $10 from $4 at UBS

UBS raised the firm’s price target on enGene (ENGN) to $10 from $4 and keeps a Neutral rating...

17d ago

JNJ

CGON

Promising Developments in CG Oncology’s NMIBC Treatment Drive Buy Recommendation

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. and keeping the price...

3d ago

CGON

CG Oncology Appoints Christina Rossi to Board

CG Oncology, Inc. ( ($CGON) ) has shared an announcement. On November 22, 2025, CG Oncology, Inc. announced...

3d ago

CGON

CG Oncology, Inc.: Promising Future with Creto’s Accelerated Approval Path and Market Differentiation

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on CGON stock, giving a Buy rating...

12d ago

CGON

Strategic Advancements and Risk Mitigation Drive Buy Rating for CG Oncology, Inc.

CG Oncology, Inc., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sean Laaman...

14d ago

CGON

CG Oncology Advances Bladder Cancer Therapy Development

CG Oncology, Inc. ( ($CGON) ) has released its Q3 earnings. Here is a breakdown of the information...

14d ago

CGON

CG Oncology Appoints Jim DeTore as Interim CFO

An announcement from CG Oncology, Inc. ( ($CGON) ) is now available. On November 10, 2025, Robert Lapetina...

15d ago

CGON

CGON FAQ

What was CG Oncology, Inc.’s price range in the past 12 months?

CG Oncology, Inc. lowest stock price was $14.80 and its highest was $45.77 in the past 12 months.

What is CG Oncology, Inc.’s market cap?

CG Oncology, Inc.’s market cap is $3.62B.

When is CG Oncology, Inc.’s upcoming earnings report date?

CG Oncology, Inc.’s upcoming earnings report date is Mar 27, 2026 which is in 118 days.

How were CG Oncology, Inc.’s earnings last quarter?

CG Oncology, Inc. released its earnings results on Nov 14, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.559 by -$0.011.

Is CG Oncology, Inc. overvalued?

According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CG Oncology, Inc. pay dividends?

CG Oncology, Inc. does not currently pay dividends.

What is CG Oncology, Inc.’s EPS estimate?

CG Oncology, Inc.’s EPS estimate is -0.61.

How many shares outstanding does CG Oncology, Inc. have?

CG Oncology, Inc. has 80,666,176 shares outstanding.

What happened to CG Oncology, Inc.’s price movement after its last earnings report?

CG Oncology, Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.559. Following the earnings report the stock price went up 8.607%.

Which hedge fund is a major shareholder of CG Oncology, Inc.?

Currently, no hedge funds are holding shares in CGON

CG Oncology, Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-24.74%

Trailing 12-Months

Asset Growth

32.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CG Oncology, Inc.

CG Oncology, Inc. (CGON) is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company primarily operates in the biopharmaceutical sector, specializing in the research and commercialization of novel cancer treatments that aim to improve patient outcomes. CGON's core product offerings include therapeutic candidates that target specific cancers, utilizing advanced drug delivery systems and proprietary technologies.

CG Oncology, Inc. (CGON) Earnings & Revenues

Historic Earnings Reports

CGON Stock 12 Month Forecast

Average Price Target

$70.09

▲(56.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","56":"$56","91":"$91","38.5":"$38.5","73.5":"$73.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$70.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,38.5,56,73.5,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.27,46.86461538461539,50.45923076923077,54.05384615384616,57.64846153846154,61.24307692307693,64.83769230769231,68.43230769230769,72.02692307692308,75.62153846153846,79.21615384615384,82.81076923076924,86.40538461538462,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.27,45.33307692307692,47.39615384615385,49.45923076923077,51.52230769230769,53.58538461538462,55.64846153846154,57.71153846153847,59.77461538461539,61.83769230769231,63.900769230769235,65.96384615384616,68.02692307692308,{"y":70.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.27,44.1723076923077,45.074615384615385,45.97692307692308,46.87923076923077,47.78153846153846,48.683846153846154,49.58615384615385,50.488461538461536,51.39076923076923,52.293076923076924,53.19538461538461,54.097692307692306,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >